Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06665594 · ClinicalTrials.gov registry record · Phase 2
Effect of TXA on Reducing Bruising After Filler Injection
A Phase 2 study of Tranexamic Acid and Facial Filler Injections, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06665594: Recruiting Phase 2 study of Tranexamic Acid and Facial Filler Injections, sponsored by University of Wisconsin, Madison.
NCT06665594 is a Phase 2 study of Tranexamic Acid and Facial Filler Injections that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 40 participants, below the 153-participant average among 3 other Tranexamic Acid trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06665594, a Phase 2 study of Tranexamic Acid and Facial Filler Injections, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is: * Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection? Participants will receive the study medication along with the standard facial filler injection and complete surveys.
Primary Outcome
Participants will score the intensity of bruising on a 5-point Likert scale, where 1 = no bruising and 5 = severe bruising.
Conditions Studied
Interventions
- PROCEDURE Hyaluronic Acid (HA)
- DRUG Tranexamic Acid (TXA)
- DRUG Saline (placebo)
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT06665594 shows while recruiting
NCT06665594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 153-participant average among 3 other Tranexamic Acid trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Tranexamic Acid appearing as the primary indexed condition, and to 3 interventions - of which Hyaluronic Acid (HA) is the first listed.
NCT06665594 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06665594 about?
NCT06665594 is a clinical study titled "Effect of TXA on Reducing Bruising After Filler Injection". The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is: * Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after ...
What is the current status of trial NCT06665594?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-12-05. Estimated completion is 2026-11.
What conditions does trial NCT06665594 study?
This clinical trial studies the following conditions: Tranexamic Acid, Facial Filler Injections, Hyaluronic Acid.
What interventions are being tested in trial NCT06665594?
The interventions under investigation include: Hyaluronic Acid (HA) (PROCEDURE), Tranexamic Acid (TXA) (DRUG), Saline (placebo) (DRUG).
Who is sponsoring clinical trial NCT06665594?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06665594 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tranexamic Acid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery
COMPLETED · NA
-
Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI